These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36850041)

  • 1. Patients' experiences with continuation or discontinuation of buprenorphine before painful procedures: A brief report.
    Hathaway DB; Bhat JA; Twark C; Rodriguez C; Suzuki J
    Am J Addict; 2023 Jul; 32(4):410-414. PubMed ID: 36850041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
    Geddes L; Iversen J; Wand H; Maher L
    Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low dose IV buprenorphine inductions for patients with opioid use disorder and concurrent pain: a retrospective case series.
    Murray JP; Pucci G; Weyer G; Ari M; Dickson S; Kerins A
    Addict Sci Clin Pract; 2023 Jun; 18(1):38. PubMed ID: 37264449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The problem of pain: Additive analgesic effect of tramadol and buprenorphine in a patient with opioid use disorder.
    Montalvo C; Genovese N; Renner J
    Subst Abus; 2019; 40(2):136-139. PubMed ID: 30835647
    [No Abstract]   [Full Text] [Related]  

  • 6. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
    Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
    Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced Inpatient Management of Opioid Use Disorder in a Patient Requiring Serial Surgeries.
    Mortaji P; Terasaki D; Moo-Young J
    J Gen Intern Med; 2021 Aug; 36(8):2448-2451. PubMed ID: 33782885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative buprenorphine continuation in stabilized buprenorphine patients: A population cohort study.
    Hauck TS; Ladha KS; Le Foll B; Wijeysundera DN; Kurdyak P
    Addiction; 2023 Oct; 118(10):1953-1964. PubMed ID: 37332171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative Continuation of Buprenorphine at Low-Moderate Doses Was Associated with Lower Postoperative Pain Scores and Decreased Outpatient Opioid Dispensing Compared with Buprenorphine Discontinuation.
    Quaye A; Potter K; Roth S; Acampora G; Mao J; Zhang Y
    Pain Med; 2020 Sep; 21(9):1955-1960. PubMed ID: 32167541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder.
    Thakrar AP; Uritsky TJ; Christopher C; Winston A; Ronning K; Sigueza AL; Caputo A; McFadden R; Olenik JM; Perrone J; Delgado MK; Lowenstein M; Compton P
    Addict Sci Clin Pract; 2023 Feb; 18(1):13. PubMed ID: 36829242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal buprenorphine for in-hospital transition from full agonist opioids to sublingual buprenorphine: a retrospective observational cohort study.
    Baumgartner K; Salmo E; Liss D; Devgun J; Mullins M; Galati B; Kelly J; Schwarz E
    Clin Toxicol (Phila); 2022 Jun; 60(6):688-693. PubMed ID: 35048759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for Continuing Buprenorphine in the Perioperative Period.
    Li AH; Schmiesing C; Aggarwal AK
    Clin J Pain; 2020 Oct; 36(10):764-774. PubMed ID: 32520814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of patient discontinuation from buprenorphine/naloxone treatment for opioid use disorder: A study of a commercially insured population in Massachusetts.
    Hasan MM; Noor-E-Alam M; Mohite P; Islam MS; Modestino AS; Peckham AM; Young LD; Young GJ
    J Subst Abuse Treat; 2021 Dec; 131():108416. PubMed ID: 34098294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative opioid requirements of patients receiving sublingual buprenorphine-naloxone: a case series.
    Martin YN; Deljou A; Weingarten TN; Schroeder DR; Sprung J
    BMC Anesthesiol; 2019 May; 19(1):68. PubMed ID: 31068127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative Pain and Opioid Dose Requirements in Patients on Sublingual Buprenorphine: A Retrospective Cohort Study for Comparison Between Postoperative Continuation and Discontinuation of Buprenorphine.
    Komatsu R; Nash M; Peperzak KA; Wu J; Dinges EM; Bollag LA
    Clin J Pain; 2021 Nov; 38(2):108-113. PubMed ID: 34723862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Experiences for Patients Receiving Buprenorphine/Naloxone for Opioid Use Disorder: A Qualitative Study of Patients' Perceptions and Attitudes.
    Young GJ; Hasan MM; Young LD; Noor-E-Alam M
    Subst Use Misuse; 2023; 58(4):512-519. PubMed ID: 36762464
    [No Abstract]   [Full Text] [Related]  

  • 17. Continuation of Buprenorphine to Facilitate Postoperative Pain Management for Patients on Buprenorphine Opioid Agonist Therapy.
    Mehta D; Thomas V; Johnson J; Scott B; Cortina S; Berger L
    Pain Physician; 2020 Mar; 23(2):E163-E174. PubMed ID: 32214293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period.
    Lembke A; Ottestad E; Schmiesing C
    Pain Med; 2019 Mar; 20(3):425-428. PubMed ID: 29452378
    [No Abstract]   [Full Text] [Related]  

  • 19. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.
    Johnson B; Richert T
    Harm Reduct J; 2019 May; 16(1):31. PubMed ID: 31046774
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.